Mats Grahn, CEO will present the IMMray™ antibody biomarker platform development pipeline and commercialisation strategies.
LUND, Sweden, Nov. 13, 2018 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), today announced that the Company has been invited to present at the Jefferies 2018 London Healthcare Conference on November 14 at 2pm local time (GMT). Mats Grahn, CEO will present the IMMray™ antibody biomarker platform development pipeline and commercialisation strategies. A live audio webcast of the presentation can be accessed via http://wsw.com/webcast/jeff115/immnov/. The webcast will be archived shortly afterwards under “Presentations” in the Investors section of the Company’s website at www.immunovia.com and be available for approximately 90 days. For more information, please contact: About Immunovia Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Immunovia AB | ||
Company Codes: Stockholm:IMMNOV |